Rockwell Medical Inc ( NASDAQ: RMTI ), a once overlooked microcap, now finds itself under investors' spotlight, largely due to its seemingly straightforward turnaround plan — ceasing spending on Triferic, a drug project that has strained the company's financial resources for decades with